熱門資訊> 正文
Aptevo Therapeutics GAAP每股收益为-9.95美元，击败2.90美元
2024-05-08 23:25
- Aptevo Therapeutics press release (NASDAQ:APVO): Q1 GAAP EPS of -$9.95 beats by $2.90.
- Aptevo had cash and cash equivalents as of March 31, 2024, totaling $10.3 million. On a proforma basis, cash, and cash equivalents as of March 31, 2024, total $14.3 million, including the proceeds from the equity raise closed on April 10, 2024.
More on Aptevo Therapeutics
- Seeking Alpha’s Quant Rating on Aptevo Therapeutics
- Historical earnings data for Aptevo Therapeutics
- Financial information for Aptevo Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
